Eppley Institute for Research in Cancer and Allied Diseases

About: Eppley Institute for Research in Cancer and Allied Diseases is a based out in . It is known for research contribution in the topics: Pancreatic cancer & Cancer. The organization has 965 authors who have published 1396 publications receiving 58994 citations.

Dietary energy restriction in the SENCAR mouse: Elevation of glucocorticoid hormone levels but no change in distribution of glucocorticoid receptor in epidermal cells

Abstract: The purpose of this study was to demonstrate that dietary energy restriction elevates plasma glucocorticoid hormone (GCH) levels while maintaining a circadian profile. Furthermore, we indirectly measured the effect of energy restriction on receptor activation in epidermis by determining the cellular localization of receptor protein in control-fed and energy-restricted (ER) mice. SENCAR mice were maintained on an ad libitum control diet or an ER diet that provided 60% of the total energy consumed by control-fed mice. Plasma corticosterone levels were determined by radioimmunoassay. Glucocorticoid receptor (GR) protein levels in epidermal lysates were measured by western blotting. Electron microscopy was used to identify gold-conjugated immunoreactive GR in epidermal cells of the skin in control and ER mice. Plasma corticosterone levels in ER mice were significantly increased 10 times over the levels in control mice at 0700 h, significantly increased two times over control levels at 1600 h, and not different from controls at 2300 h in the circadian cycle. The total amount of epidermal GR protein in ER mice was 140% (95% confidence interval, 104-169%) of that in controls at the early time point, not different at the midpoint, and 60% (95% confidence interval, 48-79%) of that in controls at the late time point. The distribution of gold-conjugated GR in the cytoplasmic and nuclear compartments of epidermal cells was similar in control and ER mice. Thus, we showed that dietary ER increased the level of plasma GCH without abolishing diurnal variation. However, an increase in ligand activation in epidermal cells, as indicated by nuclear localization of GR protein, was not supported by the results of this study.

Global analysis of human glycosyltransferases reveals novel targets for pancreatic cancer pathogenesis.

Abstract: Several reports have shown the role of glycosylation in pancreatic cancer (PC), but a global systematic screening of specific glycosyltransferases (glycoTs) in its progression remains unknown. We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry. We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems. Serial metastatic in vitro models using T3M4 and HPAF/CD18, generated in house, exhibited decreases in B3GNT3, FUT3 and GCNT3 expression on increasing metastatic potential. Immunohistochemistry identified clinical significance for GCNT3, B4GALNT3 and MGAT3 in PC. Furthermore, the effects of B3GNT3, FUT3, GCNT3 and MGAT3 were shown on proliferation, migration, EMT and stem cell markers in CD18 cell line. Talniflumate, GCNT3 inhibitor, reduced colony formation and migration in T3M4 and CD18 cells. Moreover, we found that loss of GCNT3 suppresses PC progression and metastasis by downregulating cell cycle genes and β-catenin/MUC4 axis. For GCNT3, proteomics revealed downregulation of MUC5AC, MUC1, MUC5B including many other proteins. Collectively, we demonstrate a critical role of O- and N-linked glycoTs in PC progression and delineate the mechanism encompassing the role of GCNT3 in PC.

Comparison between in vitro and in vivo tests for carcinogenicity. An overview.

Abstract: There are examples of short-term prescreening tests for carcinogenicity that fail to agree with the results of animal bioassays. Factors which may lead to such discordant results are discussed in terms of the present understanding of the mechanisms of chemical carcinogenesis and the quality of the results obtained in vivo and in vitro.

Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β.

Abstract: Pancreatic cancer (PC) is one of the most lethal malignancies and represents an increasing and challenging threat, especially with an aging population. The identification of immunogenic PC-specific upregulated antigens and an enhanced understanding of the immunosuppressive tumor microenvironment have provided opportunities to enable the immune system to recognize cancer cells. Due to its differential upregulation and functional role in PC, the transmembrane mucin MUC4 is an attractive target for immunotherapy. In the current study we characterized the antigen stability, antigenicity and release kinetics of a MUC4β-nanovaccine to guide further optimization and, in vivo evaluation. Amphiphilic polyanhydride copolymers based on 20 mol % 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane and 80 mol % 1,6-bis(p-carboxyphenoxy)hexane were used to synthesize nanoparticles. Structurally stable MUC4β protein was released from the particles in a sustained manner and characterized by gel electrophoresis and fluorescence spectroscopy. Modest levels of protein degradation were observed upon release. The released protein was also analyzed by MUC4β-specific monoclonal antibodies using ELISA and showed no significant loss of epitope availability. Further, mice immunized with multiple formulations of combination vaccines containing MUC4β-loaded nanoparticles generated MUC4β-specific antibody responses. These results indicate that polyanhydride nanoparticles are viable MUC4β vaccine carriers, laying the foundation for evaluation of this platform for PC immunotherapy.

Cystic fibrosis complicated by acute leukemia.

Abstract: During a 3-month period, two men ages 20 and 25 years, respectively, with cystic fibrosis developed acute lymphocytic and nonlymphocytic leukemias, respectively. These two patients were among 120 patients who attended our cystic fibrosis clinic during the last 3 years. Thirty-five of the 120 patients have survived beyond the second decade. The authors ask whether acute leukemia will be recognized with increasing frequency in cystic fibrosis patients who achieve prolonged survival.